Publication details
Lucentis v léčbě vlhké formy VPMD, první zkušenosti
| Title in English | Lucentis in treatment of wet form of AMD, first experience |
|---|---|
| Authors | |
| Year of publication | 2009 |
| Type | Article in Proceedings |
| Conference | Sborník 10. Vejdovského olomouckého vědeckého dne |
| MU Faculty or unit | |
| Citation | |
| Field | ORL, ophthalmology, stomatology |
| Keywords | age related macular degeneration; choroidal neovascular membrane; vascular endothelial growth factor; ranibizumab |
| Description | The authors evaluated results achieved with the use of ranibizumab (Lucentis) for wet age-related macular degeneration (AMD). Ranibizumab (Lucentis, Novartis) is an antagonist of vascular endothelial growth factor (VEGF), approved for intraocular injection in wet form of age-related macular degeneration (AMD). Ranibizumab in our department used to treat patients with occult, minimally classic or predominantly classic subretinal neovascular membrane (CNV) in the subfoveal location. Patients included in the study are treated with 3 application ranibizumab every 1 month (loading phase), followed by applications as needed - the maintenance phase (ie, if a decrease visual acuity by more than 5 ETDRS letters, or edema will increase by more than 100 um). Treatment of patients at the time of writing the abstract is still ongoing. Results will be presented to Congress on the ground to achieve the longest follow-up period for all subjects included in the file. |